ClinicalTrials.gg
CompletedNCT02253654Updated May 19, 2017Results posted

Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis

A Phase 4 interventional study of Epoetin alfa in Renal Insufficiency, Chronic, Anemia and Renal Dialysis, sponsored by Amgen. Completed at 37 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-19.

Sponsored by Amgen · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic — 1 open to participants now, 1 under way, none of them phase 3. Epoetin Alfa · Renal Insufficiency, Chronic.

Enrollment
12th of 25
216 · median 157
Started
2015
with 1 other
Phase 4
7 of 25
none open now
Registered
21st of 25
by date
Lead sponsor
2 of 25
Amgen

Among the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, this one is the 12th largest by enrollment, is one of 2 that started in 2015, is one of 7 in phase 4, and was the 21st registered.

Renal Insufficiency, Chronic

3,096 studies on the registry are indexed under Renal Insufficiency, Chronic; 701 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

1 of the 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Epoetin Alfa

Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 435 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 44 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing Epoetin Alfa in Renal Insufficiency, Chronic, or all of them as a file.
02

Study summary

The purpose of this study is to compare two different dosing methods of epoetin alfa and their effectiveness in maintaining hemoglobin levels between 10.0 to 11.0 g/dL in in patients with chronic kidney disease (CKD) receiving hemodialysis.

03

Conditions studied

  • Renal Insufficiency, Chronic
  • Anemia
  • Renal Dialysis
  • Erythrocyte Transfusion

Keywords

  • Chronic Kidney Disease
  • Anemia
  • Hemodialysis
  • Red Blood Cell Transfusion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained prior to initiation of any study-specific activities/procedures
  • Age 18 or older
  • Prescribed hemodialysis three times a week (TIW) for ≥ 12 weeks prior to randomization
  • Prescribed IV administration of epoetin alfa TIW for ≥ 12 weeks prior to randomization
  • Prescribed ≥ 3000 Units/week (ie, ≥ 1000 Units/administration) and \< 90,000 Units/week (ie, \< 30,000 Units/administration) of epoetin alfa during the 4 weeks prior to randomization
  • Received ≥ 4 doses of epoetin alfa during the 2 weeks prior to randomization
  • concentration ≤ 11.0 g/dL, per the most recent local laboratory value obtained during the 2 weeks prior to randomization
  • Hemoglobin concentration ≤ 11.0 g/dL, at the screening visit, using the hemoglobin point of care device provided by Amgen
  • Iron replete, defined as a transferrin saturation (TSAT) ≥ 20% and a ferritin ≥ 100 ng/mL, per the most recent local laboratory value obtained during the 4 weeks prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Currently receiving treatment in another device or drug study, or less than 30 days since ending treatment on another investigational device or drug study(s) prior to randomization
  • Other investigational procedures while participating in this study are excluded
  • Systemic hematologic disease (eg, sickle cell anemia, myelodysplastic syndrome, hematologic )
  • Current or prior malignancy within 5 years of randomization, with the exception of non-melanoma skin cancers, cervical or breast ductal carcinoma in situ
  • Treatment for any malignancy (eg, radiation, chemotherapy, hormone therapy or biologics) within 5 years of randomization, with the exception of locally excised non-melanoma skin cancers, cervical or breast ductal carcinoma in situ
  • Subject is currently pregnant or planning to become pregnant during treatment and for 30 days after the end of treatment
  • Subject is currently breast feeding or planning on breast feeding during treatment and for 30 days after the end of treatment
  • Females of who are not willing to use an acceptable method of effective during treatment and for at least 30 days after the end of treatment
  • Currently receiving IV antibiotics
  • Currently receiving systemic therapy known to cause anemia, including treatment for active hepatitis (eg, azathioprine, mycophenolate mofetil, ≥ 10 mg prednisone [or equivalent]/day, interferon)
  • Known (HIV) positive
  • Known neutralizing anti-erythropoietic protein antibodies
  • Known sensitivity to epoetin alfa
  • Subject likely to not be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures (eg, planned vacations where away from dialysis unit for more than 2 weeks) to the best of the subject and investigator's knowledge
  • History or evidence of any other disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion
  • Previously entered this study
  • Occurrence of any of the following within 8 weeks prior to randomization:

    • Seizure
    • Clinically relevant active bleeding (eg, gastrointestinal bleed)
    • RBC transfusion
    • Any hospitalization or observational stay > 24 hours
  • Uncontrolled hypertension, per the investigator within the 4 weeks prior to randomization
  • Expected or scheduled solid organ transplant(eg, kidney) within 40 weeks after randomization
  • Expected or scheduled to change dialysis modality (eg, peritoneal dialysis, home hemodialysis) within 40 weeks after randomization
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Epoetin alfa Alternative Titration

    Participants received epoetin alfa administered intravenously three times a week during hemodialysis for up to 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose changes may have occurred every 2 weeks according to the alternative dosing algorithm, where smaller, frequent dose adjustments were permitted based on six hemoglobin categories.

    Drug: Epoetin alfa

  • Active comparator
    Epoetin alfa USPI Titration

    Participants received epoetin alfa administered intravenously three times a week during hemodialysis for 37 weeks. For the first two weeks the dose of epoetin alfa was based on the dose at the time of screening. Beginning at week 3 dose decreases were permitted every 2 weeks and beginning at week 5 dose increases could only occur ≥ 4 weeks from the last dose increase, according to the United States package insert (USPI) dosing algorithm which includes four categories of hemoglobin levels.

    Drug: Epoetin alfa

Interventions

  • Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.

    Also known as: Epogen

06

What researchers measure

Primary outcomes

  1. Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period

    Hemoglobin was measured every 2 weeks during the evaluation period. The percentage of these measurements that were within the range of 10-11 g/dL was calculated for each participant.

    Time frame: The evaluation period (weeks 13-37)

Secondary outcomes

  1. Hemoglobin Concentration at Each Visit

    Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37

  2. Percentage of Participants With Transfusion Events Overall and During Each Study Period

    The percentage of participants who received red blood cell (RBC) transfusions during the study and during each study period.

    Time frame: Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41

  3. Hemoglobin Rate of Change at Each Visit

    Hemoglobin rate of change (ROC) was calculated for each visit using the following formula: ROC = (current visit hemoglobin value - previous visit hemoglobin value) / number of days between each visit \* 14. A positive value indicates a rate of rise and a negative value indicates a rate of decline.

    Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37

  4. Hemoglobin Intra-subject Variability

    Intra-subject variability was defined for each participant as the standard deviation (SD) of all of the hemoglobin concentrations during the evaluation period for the participant. The mean intra-subject SD for all participants is the sum of the intra-subject SDs divided by the total number of participants evaluated.

    Time frame: The evaluation period (weeks 13 to 37)

  5. Percentage of Participants With Hemoglobin Excursions at Each Visit

    An excursion is identified as an event when a hemoglobin concentration fell below or exceeded the pre-specified thresholds of: - \< 9.0 g/dL, or - \> 11.0 g/dL, or - \> 12.0 g/dL. The percentage of participants with any excursions and excursions in each subcategory at each time point and overall during the study are reported.

    Time frame: Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37

  6. Weekly Epoetin Alfa Dose at Each Visit

    Time frame: Weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35

  7. Number of RBC Units Transfused Overall and During Each Study Period

    The number of red blood cell (RBC) units transfused during the study and during each study period.

    Time frame: Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41

07

Results

Posted May 12, 2017

Participant flow

This study was conducted at 31 centers in the United States. Participants were enrolled from 01 April 2015 to 17 August 2015.

Participant flow — Overall Study
MilestoneEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Started108108
Received treatment104107
Completed8590
Not completed2318
Withdrew: Withdrawal by subject124
Withdrew: Decision by sponsor11
Withdrew: Lost to follow-up25
Withdrew: Death47
Withdrew: Did not receive study treatment41

Outcome measures

PrimaryPercentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period

Hemoglobin was measured every 2 weeks during the evaluation period. The percentage of these measurements that were within the range of 10-11 g/dL was calculated for each participant.

Time frame:
The evaluation period (weeks 13-37)
Reported as:
Mean · percentage of hemoglobin measurements
Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period
percentage of hemoglobin measurementsEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Percentage of Hemoglobin Measurements Within 10 to 11 g/dL During the Evaluation Period46.41 ± 2.3946.02 ± 2.56
Statistical analysis
  • Epoetin Alfa Alternative Titration vs Epoetin Alfa USPI Titration · t-test, 1 sided · p = 0.46 · Treatment difference: 0.39
SecondaryHemoglobin Concentration at Each Visit
Time frame:
Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Reported as:
Mean · g/dL
Hemoglobin Concentration at Each Visit
g/dLEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Baseline (n = 89, 100)10.15 ± 0.6610.04 ± 0.81
Week 3 (n = 89, 100)10.54 ± 0.8810.34 ± 0.97
Week 5 (n = 89, 99)10.66 ± 0.9310.51 ± 1.04
Week 7 (n = 88, 97)10.45 ± 1.0210.28 ± 1.07
Week 9 (n = 89, 100)10.32 ± 1.169.97 ± 0.87
Week 11 (n = 88, 99)10.33 ± 1.0510.15 ± 0.88
Week 13 (n = 89, 100)10.28 ± 1.049.99 ± 0.91
Week 15 (n = 89, 100)10.46 ± 1.389.98 ± 0.93
Week 17 (n = 89, 100)10.20 ± 1.0510.01 ± 1.22
Week 19 (n = 89, 100)10.37 ± 1.149.94 ± 0.87
Week 21 (n = 87, 99)10.33 ± 1.019.92 ± 0.81
Week 23 (n = 88, 98)10.46 ± 1.0510.03 ± 0.86
Week 25 (n = 87, 98)10.56 ± 1.009.94 ± 0.97
Week 27 (n = 88, 94)10.32 ± 1.109.97 ± 0.86
Week 29 (n =89, 92)10.34 ± 1.0110.02 ± 1.07
Week 31 (n = 85, 89)10.34 ± 0.959.96 ± 1.07
Week 33 (n = 86, 90)10.18 ± 1.0010.05 ± 0.92
Week 35 (n = 87, 88)10.12 ± 1.239.94 ± 0.90
Week 37 (n = 87, 93)10.10 ± 1.119.86 ± 0.85
SecondaryPercentage of Participants With Transfusion Events Overall and During Each Study Period

The percentage of participants who received red blood cell (RBC) transfusions during the study and during each study period.

Time frame:
Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41
Reported as:
Number · percentage of participants
Percentage of Participants With Transfusion Events Overall and During Each Study Period
percentage of participantsEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Overall (n = 89, 100)6.712.0
Titration Period (n = 89, 100)2.21.0
Evaluation Period (n = 89, 100)5.610.0
Safety Follow-up Period (n = 83, 90)1.21.1
SecondaryHemoglobin Rate of Change at Each Visit

Hemoglobin rate of change (ROC) was calculated for each visit using the following formula: ROC = (current visit hemoglobin value - previous visit hemoglobin value) / number of days between each visit \* 14. A positive value indicates a rate of rise and a negative value indicates a rate of decline.

Time frame:
Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Reported as:
Mean · g/dL/2 weeks
Hemoglobin Rate of Change at Each Visit
g/dL/2 weeksEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Week 3 (n = 89, 100)0.36 ± 0.790.27 ± 0.71
Week 5 (n = 89, 99)0.10 ± 0.810.13 ± 1.01
Week 7 (n = 88, 97)-0.22 ± 0.90-0.19 ± 1.42
Week 9 (n = 89, 100)-0.12 ± 0.93-0.28 ± 1.08
Week 11 (n = 88, 99)0.02 ± 1.010.19 ± 0.67
Week 13 (n = 89, 100)-0.05 ± 0.93-0.19 ± 0.97
Week 15 (n = 89, 100)0.19 ± 1.01-0.01 ± 0.87
Week 17 (n = 89, 100)-0.22 ± 1.080.02 ± 1.07
Week 19 (n = 89, 100)0.18 ± 0.97-0.06 ± 1.25
Week 21 (n = 87, 99)-0.02 ± 0.74-0.06 ± 0.72
Week 23 (n = 88, 98)0.16 ± 0.870.09 ± 0.78
Week 25 (n = 87, 98)0.07 ± 0.78-0.06 ± 0.84
Week 27 (n = 88, 94)-0.18 ± 0.770.01 ± 0.85
Week 29 (n =89, 92)0.04 ± 0.860.05 ± 0.73
Week 31 (n = 85, 89)-0.02 ± 0.72-0.03 ± 0.74
Week 33 (n = 86, 90)-0.16 ± 0.820.06 ± 0.74
Week 35 (n = 87, 88)-0.05 ± 0.98-0.13 ± 0.72
Week 37 (n = 87, 93)-0.04 ± 1.00-0.03 ± 0.64
SecondaryHemoglobin Intra-subject Variability

Intra-subject variability was defined for each participant as the standard deviation (SD) of all of the hemoglobin concentrations during the evaluation period for the participant. The mean intra-subject SD for all participants is the sum of the intra-subject SDs divided by the total number of participants evaluated.

Time frame:
The evaluation period (weeks 13 to 37)
Reported as:
Mean · g/dL
Hemoglobin Intra-subject Variability
g/dLEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Hemoglobin Intra-subject Variability0.74 ± 0.300.70 ± 0.32
SecondaryPercentage of Participants With Hemoglobin Excursions at Each Visit

An excursion is identified as an event when a hemoglobin concentration fell below or exceeded the pre-specified thresholds of: - \< 9.0 g/dL, or - \> 11.0 g/dL, or - \> 12.0 g/dL. The percentage of participants with any excursions and excursions in each subcategory at each time point and overall during the study are reported.

Time frame:
Baseline (screening visit) and weeks 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, and 37
Reported as:
Number · percentage of participants
Percentage of Participants With Hemoglobin Excursions at Each Visit
percentage of participantsEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Overall Excursions (n = 89, 100)91.093.0
Overall Excursions < 9.0 (n = 89, 100)48.361.0
Overall Excursions > 11.0 (n = 89, 100)80.983.0
Overall Excursions > 12.0 (n = 89, 100)25.819.0
Baseline Excursions (n = 89, 100)3.411.0
Baseline Excursions < 9.0 (n = 89, 100)3.411.0
Baseline Excursions > 11.0 (n = 89, 100)0.00.0
Baseline Excursions > 12.0 (n = 89, 100)0.00.0
Week 3 Excursions (n = 89, 100)29.227.0
Week 3 Excursions < 9.0 (n = 89, 100)2.26.0
Week 3 Excursions > 11.0 (n = 89, 100)27.021.0
Week 3 Excursions > 12.0 (n = 89, 100)5.65.0
Week 5 Excursions (n = 89, 99)36.029.3
Week 5 Excursions < 9.0 (n = 89, 99)1.14.0
Week 5 Excursions > 11.0 (n = 89, 99)34.825.3
Week 5 Excursions > 12.0 (n = 89, 99)5.67.1
Week 7 Excursions (n = 88, 97)27.328.9
Week 7 Excursions < 9.0 (n = 88, 97)6.88.2
Week 7 Excursions > 11.0 (n = 88, 97)20.520.6
Week 7 Excursions > 12.0 (n = 88, 97)3.44.1
Week 9 Excursions (n = 89, 100)29.217.0
Week 9 Excursions < 9.0 (n = 89, 100)9.010.0
Week 9 Excursions > 11.0 (n = 89, 100)20.27.0
Week 9 Excursions > 12.0 (n = 89, 100)3.40.0
Week 11 Excursions (n = 88, 99)22.723.2
Week 11 Excursions < 9.0 (n = 88, 99)4.57.1
Week 11 Excursions > 11.0 (n = 88, 99)18.216.2
Week 11 Excursions > 12.0 (n = 88, 99)2.31.0
Week 13 Excursions (n = 89, 100)25.821.0
Week 13 Excursions < 9.0 (n = 89, 100)7.99.0
Week 13 Excursions > 11.0 (n = 89, 100)18.012.0
Week 13 Excursions > 12.0 (n = 89, 100)4.51.0
Week 15 Excursions (n = 89, 100)27.024.0
Week 15 Excursions < 9.0 (n = 89, 100)5.613.0
Week 15 Excursions > 11.0 (n = 89, 100)21.311.0
Week 15 Excursions > 12.0 (n = 89, 100)6.70.0
Week 17 Excursions (n = 89, 100)23.621.0
Week 17 Excursions < 9.0 (n = 89, 100)9.012.0
Week 17 Excursions > 11.0 (n = 89, 100)14.69.0
Week 17 Excursions > 12.0 (n = 89, 100)4.53.0
Week 19 Excursions (n = 89, 100)28.119.0
Week 19 Excursions < 9.0 (n = 89, 100)9.013.0
Week 19 Excursions > 11.0 (n = 89, 100)19.16.0
Week 19 Excursions > 12.0 (n = 89, 100)9.00.0
Week 21 Excursions (n = 87, 99)27.617.2
Week 21 Excursions < 9.0 (n = 87, 99)8.012.1
Week 21 Excursions > 11.0 (n = 87, 99)19.55.1
Week 21 Excursions > 12.0 (n = 87, 99)3.40.0
Week 23 Excursions (n = 88, 98)29.520.4
Week 23 Excursions < 9.0 (n = 88, 98)6.810.2
Week 23 Excursions > 11.0 (n = 88, 98)22.710.2
Week 23 Excursions > 12.0 (n = 88, 98)5.70.0
Week 25 Excursions (n = 87, 98)28.720.4
Week 25 Excursions < 9.0 (n = 87, 98)2.313.3
Week 25 Excursions > 11.0 (n = 87, 98)26.47.1
Week 25 Excursions > 12.0 (n = 87, 98)5.72.0
Week 27 Excursions (n = 88, 94)29.521.3
Week 27 Excursions < 9.0 (n = 88, 94)10.216.0
Week 27 Excursions > 11.0 (n = 88, 94)19.35.3
Week 27 Excursions > 12.0 (n = 88, 94)3.40.0
Week 29 Excursions (n = 89, 92)25.829.3
Week 29 Excursions < 9.0 (n = 89, 92)5.616.3
Week 29 Excursions > 11.0 (n = 89, 92)20.213.0
Week 29 Excursions > 12.0 (n = 89, 92)4.52.2
Week 31 Excursions (n = 85, 89)20.028.1
Week 31 Excursions < 9.0 (n = 85, 89)4.716.9
Week 31 Excursions > 11.0 (n = 85, 89)15.311.2
Week 31 Excursions > 12.0 (n = 85, 89)5.91.1
Week 33 Excursions (n = 86, 90)22.122.2
Week 33 Excursions < 9.0 (n = 86, 90)7.011.1
Week 33 Excursions > 11.0 (n = 86, 90)15.111.1
Week 33 Excursions > 12.0 (n = 86, 90)3.52.2
Week 35 Excursions (n = 87, 88)26.421.6
Week 35 Excursions < 9.0 (n = 87, 88)11.513.6
Week 35 Excursions > 11.0 (n = 87, 88)14.98.0
Week 35 Excursions > 12.0 (n = 87, 88)4.60.0
Week 37 Excursions (n = 87, 93)20.717.2
Week 37 Excursions < 9.0 (n = 87, 93)8.012.9
Week 37 Excursions > 11.0 (n = 87, 93)12.64.3
Week 37 Excursions > 12.0 (n = 87, 93)3.40.0
SecondaryWeekly Epoetin Alfa Dose at Each Visit
Time frame:
Weeks 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, and 35
Reported as:
Mean · units
Weekly Epoetin Alfa Dose at Each Visit
unitsEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Week 1 (n = 89, 100)13139.9 ± 9360.110400 ± 8439.9
Week 3 (n = 89, 100)9683.7 ± 9162.96912.5 ± 7459.4
Week 5 (n = 89, 100)8324.2 ± 8689.76874.0 ± 8204.3
Week 7 (n = 89, 100)9319.1 ± 7977.56411.0 ± 7040.6
Week 9 (n = 89, 100)9253.4 ± 8536.98003.0 ± 7292.8
Week 11 (n = 89, 100)10039.3 ± 9194.16483.0 ± 6854.9
Week 13 (n = 89, 100)10358.4 ± 10247.77387.5 ± 7271.6
Week 15 (n = 89, 100)8889.3 ± 8316.86874.5 ± 5952.9
Week 17 (n = 89, 100)10251.7 ± 9973.76924.5 ± 6211.1
Week 19 (n = 89, 100)10475.8 ± 10437.07112.5 ± 6300.4
Week 21 (n = 89, 99)9605.1 ± 8225.06909.6 ± 6102.5
Week 23 (n = 89, 98)8905.1 ± 7748.36830.1 ± 6397.0
Week 25 (n = 89, 98)7543.8 ± 7225.17486.7 ± 6676.2
Week 27 (n = 89, 96)9765.7 ± 12013.76662.5 ± 6362.8
Week 29 (n =89, 94)9088.8 ± 10146.96083.0 ± 6149.1
Week 31 (n = 88, 91)8543.2 ± 10821.76673.1 ± 6277.6
Week 33 (n = 87, 90)9019.0 ± 10466.96235.6 ± 6041.6
Week 35 (n = 87, 90)8709.2 ± 8631.95950.6 ± 5364.6
SecondaryNumber of RBC Units Transfused Overall and During Each Study Period

The number of red blood cell (RBC) units transfused during the study and during each study period.

Time frame:
Overall Study: Study week 1 to week 41; Titration Period: Study week 1 to week 12; Evaluation Period: Study week 13 to week 37; Safety Follow-up Period: Study week 38 to week 41
Reported as:
Number · participants
Number of RBC Units Transfused Overall and During Each Study Period
participantsEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Overall Study: 1 RBC Unit (n = 89, 100)14
Overall Study: 2 RBC Units (n = 89, 100)25
Overall Study: 3 RBC Units (n = 89, 100)12
Overall Study: > 3 RBC Units (n = 89, 100)21
Titration Period: 1 RBC Unit (n = 89, 100)01
Titration Period: 2 RBC Units (n = 89, 100)10
Titration Period: 3 RBC Units (n = 89, 100)10
Titration Period: > 3 RBC Units (n = 89, 100)00
Evaluation Period: 1 RBC Unit (n = 89, 100)13
Evaluation Period: 2 RBC Units (n = 89, 100)34
Evaluation Period: 3 RBC Units (n = 89, 100)12
Evaluation Period: > 3 RBC Units (n = 89, 100)01
Safety Follow-up Period: 1 RBC Unit (n = 83, 90)00
Safety Follow-up Period: 2 RBC Units (n = 83, 90)11
Safety Follow-up Period: 3 RBC Units (n = 83, 90)00
Safety Follow-up Period: >3 RBC Units (n = 83, 90)00

Adverse events

Collected over 41 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epoetin Alfa Alternative Titration—37/104 (35.6%)19/104 (18.3%)
Epoetin Alfa USPI Titration—39/107 (36.4%)26/107 (24.3%)
Most frequent serious events
Showing 10 of 107
Most frequent serious events
EventEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
Fluid overloadMetabolism and nutrition disorders3/1049/107
PneumoniaInfections and infestations2/1046/107
Cerebrovascular accidentNervous system disorders0/1044/107
Cardiac arrestCardiac disorders3/1041/107
Cardiac failure congestiveCardiac disorders3/1042/107
HyperkalaemiaMetabolism and nutrition disorders3/1041/107
Gastrointestinal haemorrhageGastrointestinal disorders2/1043/107
Pleural effusionRespiratory, thoracic and mediastinal disorders1/1043/107
Non-cardiac chest painGeneral disorders2/1040/107
Cholecystitis acuteHepatobiliary disorders2/1040/107
Most frequent other events
Most frequent other events
EventEpoetin Alfa Alternative TitrationEpoetin Alfa USPI Titration
DiarrhoeaGastrointestinal disorders8/1048/107
HypertensionVascular disorders5/1048/107
AnaemiaBlood and lymphatic system disorders2/1047/107
DyspnoeaRespiratory, thoracic and mediastinal disorders6/1044/107
Haemoglobin increasedInvestigations3/1046/107

Baseline characteristics

All randomized participants

Age, Continuous
Age, Continuous(years)Epoetin Alfa Alternative TitrationEpoetin Alfa USPI TitrationTotal
Mean60.9 ± 13.358.7 ± 14.259.8 ± 1.8
Sex: Female, Male
Sex: Female, Male(Participants)Epoetin Alfa Alternative TitrationEpoetin Alfa USPI TitrationTotal
Female484088
Male6068128
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Epoetin Alfa Alternative TitrationEpoetin Alfa USPI TitrationTotal
Asian7714
Black5350103
Native Hawaiian or other Pacific Islander011
White404080
Other81018
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Epoetin Alfa Alternative TitrationEpoetin Alfa USPI TitrationTotal
Hispanic/Latino303969
Not Hispanic/Latino7869147
08

Study locations

37 sites
  • Research Site
    Cerritos, California 90703, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Los Angeles, California 90057, United States
  • Research Site
    Montebello, California 90640, United States
  • Research Site
    Riverside, California 92501, United States
  • Research Site
    San Diego, California 92115, United States
  • Research Site
    Simi Valley, California 93065, United States
  • Research Site
    Vacaville, California 95687, United States
  • Research Site
    Whittier, California 90606, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Miami Gardens, Florida 33169, United States
  • Research Site
    Pembroke Pines, Florida 33025, United States
  • Research Site
    Macon, Georgia 31217, United States
  • Research Site
    Statesboro, Georgia 30458, United States
  • Research Site
    Merrillville, Indiana 46410, United States
  • Research Site
    Michigan City, Indiana 46360, United States
  • Research Site
    Detroit, Michigan 48202, United States
  • Research Site
    Pontiac, Michigan 48341, United States
  • Research Site
    Roseville, Michigan 48066, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Lincoln, Nebraska 68510, United States
  • Research Site
    Astoria, New York 11102, United States
  • Research Site
    Brooklyn, New York 11235, United States
  • Research Site
    Rosedale, New York 11422, United States
  • Research Site
    The Bronx, New York 10461, United States
  • Research Site
    Carrboro, North Carolina 27510, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Meadville, Pennsylvania 16335, United States
  • Research Site
    Philadelphia, Pennsylvania 19106, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77070, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    Burlington, Vermont 05401, United States
  • Research Site
    Hampton, Virginia 23666, United States
  • Research Site
    Norfolk, Virginia 23502, United States
  • Research Site
    Toa Baja, 00949, Puerto Rico
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2015 to primary completion in Apr 2016, 12 months.

Results were first posted in May 2017, 1 year after primary completion.

Of 116 phase 4 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2014
First posted
Oct 1, 2014
StartActual
Apr 1, 2015
Primary completionActual
Apr 27, 2016
CompletionActual
May 25, 2016
Results first posted
May 12, 2017
Last update
May 19, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02253654
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Oct 1, 2014
Start date
Apr 1, 2015
Primary completion
Apr 27, 2016
Completion
May 25, 2016
Results posted
May 12, 2017
Last update
May 19, 2017

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Epoetin Alfa

Start the discussion